RESEARCH · NAD+ · AGEING & HUMAN TISSUE DATA
Does NAD+ Decline With Age in Humans? The Tissue-by-Tissue Evidence and How It Was Measured
PurixLab’s NAD+ 500mg is a research vial of nicotinamide adenine dinucleotide, a coenzyme rather than a peptide. Our earlier articles cover coenzyme biology, CD38 and PARP, how NAD is measured, membrane transport, NR and NMN precursor trials and stability and storage. This article asks a narrower question that underpins much of the field: what is the direct human evidence that NAD+ declines with age, which tissues were studied, and how was it measured? The studies below describe human volunteers, patients and animal models in published research; the vial is supplied for laboratory research use only, and nothing here is a health claim about any PurixLab product.
Where the claim comes from
A 2021 review traced the idea back to reports in the early 2000s that NAD+ declines with ageing, which encouraged the view that NAD+ metabolism is globally and progressively impaired. After collecting studies in yeast, worms, rodents, monkeys and humans, the authors concluded that the evidence for an overall decline is very limited and often restricted to a single tissue or cell type, that this is particularly true in humans, and that much larger, preferably longitudinal, studies are needed [1]. Animal work also suggests the change may be modest. Using isotope tracing and mass spectrometry, one mouse study found a median tissue NAD+ decrease of about 30% in aged animals, with biosynthetic flux maintained and the shortfall attributed to faster consumption [2].
Skin: the first tissue-level human data
One of the earliest human tissue studies analysed pelvic skin removed during unrelated surgery from 49 people, including newborns and patients aged 15-77 years. NAD+ correlated negatively with age in both males (r = −0.706) and females (r = −0.537). In males, PARP activity rose with age and correlated inversely with NAD+, and SIRT1 activity fell with age; these associations were less evident in females [3]. The design was cross-sectional and the samples came from a single anatomical site, so the data show association with age rather than change within a person.
Brain and cerebrospinal fluid
A phosphorus magnetic resonance spectroscopy (MRS) assay at high field reported age-dependent reductions in NAD+, total NAD and the NAD+/NADH redox potential in healthy volunteers, together with an age-dependent increase in NADH [4]. A proton MRS method at 7T, tested for reproducibility in 11 volunteers with a within-session coefficient of variation of 6.14%, found an age-dependent decline in occipital NAD+ across 16 healthy subjects aged 26-78 years, with a slope of −1.24 micromolar per year [5]. A whole-brain phosphorus-31 spectroscopic imaging study at 7 Tesla measured NAD at approximately 0.4 mM, and its preliminary age analysis also suggested a decrease [6].
Cerebrospinal fluid (CSF) gives a less direct view. In CSF collected from healthy people aged 24-91 years during spinal anaesthesia, participants older than 45 had lower NAD(H) than younger participants, at a borderline p = 0.05. CSF and plasma NAD(H) were positively associated, and higher alcohol intake was linked to lower CSF NAD(H), an example of a lifestyle factor that can confound age comparisons [7].
Muscle and liver
In a cross-sectional comparison of muscle biopsies, NAD+ was one of the most prominent metabolites that was lower in older adults than in young adults. The difference was larger in physically impaired older people, while exercise-trained older people had NAD+ levels closer to those of young adults, and NAD+ correlated with daily step count and with mitochondrial and muscle function [8]. A 2026 multi-omics follow-up from the same research group found that 50% of the age-related gene-expression differences seen in older adults were absent in trained older adults, and linked mitochondrial respiration, lipid metabolism and NAD+ biology [9].
For human liver, a 2016 study reported lower hepatic NAD+ in aged humans as well as aged mice, with compromised NAMPT-controlled salvage but not de novo synthesis in elderly livers. Most of that paper, however, concerns mouse models of fatty liver disease [10].
Blood: where the data disagree
Using liquid chromatography-tandem mass spectrometry in plasma from healthy people aged 20-87 years, one study found significant age-related declines in NAD+, NADP+ and nicotinic acid adenine dinucleotide (NAAD), with increases in NADH, NADPH, nicotinamide, N-methyl-nicotinamide and ADP-ribose, while NMN showed no significant change [11]. A whole-blood metabolomics study comparing 15 young and 15 elderly donors listed NAD+ and NADP+ among 14 compounds with marked age-related differences, and noted that many such compounds are enriched in red blood cells [12].
Larger studies are less consistent. In a community cohort of 1,518 adults measured by cycling assay and mass spectrometry, mean whole-blood NAD+ was 33.0 µmol/L and higher in men than in women (34.5 vs 31.3 µmol/L). A decline with age was seen before 50 years, reaching significance in the 40-49 year group, but the trend disappeared after 50, and in women NAD+ did not differ significantly across age groups [13]. A 2026 analysis of seven independent cohorts, using a rigorously validated high-resolution mass-spectrometry system designed to account for real-world analytical variability, found whole-blood NAD+ remarkably stable with age and across lifestyle interventions, while it did change after nicotinamide riboside supplementation [14]. Diet may also matter: in 100 healthy middle-aged adults, plasma NAD+ was lower with higher protein intake and higher plasma urea, independent of age [15].
Why the results diverge
- Compartment. Plasma, whole blood, CSF and solid tissue are different pools. Whole-blood values largely reflect red blood cells [12], whereas plasma NAD+ is extracellular [11].
- Method. Cycling assays, LC-MS and MRS differ in specificity, and pre-analytical handling affects labile NAD species; the 2026 cohort study explicitly built analytical variability into its validation [14]. Our measurement article covers these methods in more detail.
- Who is compared. Sex [3,13], physical activity [8], alcohol [7] and diet [15] all shifted NAD measures in these studies.
- Design. Nearly all human data are cross-sectional, which is why reviewers call for longitudinal studies [1].
- Concentration versus flux. A lower concentration does not necessarily mean lower production; in aged mice flux was maintained [2].
What remains open
- Whether NAD+ falls within the same people over time, which no study here measured longitudinally [1].
- Whether in-vivo brain declines seen in small MRS studies hold in larger samples [5,6].
- Whether blood NAD+ is a useful marker of ageing at all [14,13].
- How much of the apparent age effect in muscle reflects inactivity rather than age [8,9].
None of this literature concerns a specific laboratory reagent, which is why batch documentation matters.
NAD+ 500mg at PurixLab
NAD+ 500mg: a labelled lyophilized research vial with 500mg per vial, C$109 per vial (CAD, before tax), supplied for laboratory research only. NAD+ is a coenzyme, not a peptide. Batch documentation is available on request. Product page: purixlab.com/product/nad-500mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Peluso A, Damgaard MV, Mori MAS, et al. Age-Dependent Decline of NAD+-Universal Truth or Confounded Consensus? Nutrients. 2021;14(1):101. PubMed 35010977 · PMC8747183 · doi:10.3390/nu14010101
- McReynolds MR, Chellappa K, Chiles E, et al. NAD+ flux is maintained in aged mice despite lower tissue concentrations. Cell Syst. 2021;12(12):1160-1172.e4. PubMed 34559996 · PMC8678178 · doi:10.1016/j.cels.2021.09.001
- Massudi H, Grant R, Braidy N, et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. 2012;7(7):e42357. PubMed 22848760 · PMC3407129 · doi:10.1371/journal.pone.0042357
- Zhu XH, Lu M, Lee BY, et al. In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences. Proc Natl Acad Sci U S A. 2015;112(9):2876-81. PubMed 25730862 · PMC4352772 · doi:10.1073/pnas.1417921112
- Bagga P, Hariharan H, Wilson NE, et al. Single-Voxel 1 H MR spectroscopy of cerebral nicotinamide adenine dinucleotide (NAD+ ) in humans at 7T using a 32-channel volume coil. Magn Reson Med. 2020;83(3):806-814. PubMed 31502710 · PMC6879788 · doi:10.1002/mrm.27971
- Guo R, Yang S, Wiesner HM, et al. Mapping intracellular NAD content in entire human brain using phosphorus-31 MR spectroscopic imaging at 7 Tesla. Front Neurosci. 2024;18:1389111. PubMed 38911598 · PMC11190064 · doi:10.3389/fnins.2024.1389111
- Guest J, Grant R, Mori TA, et al. Changes in oxidative damage, inflammation and [NAD(H)] with age in cerebrospinal fluid. PLoS One. 2014;9(1):e85335. PubMed 24454842 · PMC3891813 · doi:10.1371/journal.pone.0085335
- Janssens GE, Grevendonk L, Perez RZ, et al. Healthy aging and muscle function are positively associated with NAD+ abundance in humans. Nat Aging. 2022;2(3):254-263. PubMed 37118369 · doi:10.1038/s43587-022-00174-3
- Janssens GE, Trętowicz MM, Grevendonk L, et al. Delayed molecular aging, preservation of energy metabolism and enhanced exercise response in exercise-trained human muscle. Nat Aging. 2026;6(7):1482-1500. PubMed 42399371 · doi:10.1038/s43587-026-01150-x
- Zhou CC, Yang X, Hua X, et al. Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing. Br J Pharmacol. 2016;173(15):2352-68. PubMed 27174364 · PMC4945761 · doi:10.1111/bph.13513
- Clement J, Wong M, Poljak A, et al. The Plasma NAD+ Metabolome Is Dysregulated in "Normal" Aging. Rejuvenation Res. 2019;22(2):121-130. PubMed 30124109 · PMC6482912 · doi:10.1089/rej.2018.2077
- Chaleckis R, Murakami I, Takada J, et al. Individual variability in human blood metabolites identifies age-related differences. Proc Natl Acad Sci U S A. 2016;113(16):4252-9. PubMed 27036001 · PMC4843419 · doi:10.1073/pnas.1603023113
- Yang F, Deng X, Yu Y, et al. Association of Human Whole Blood NAD+ Contents With Aging. Front Endocrinol (Lausanne). 2022;13:829658. PubMed 35388296 · PMC8979162 · doi:10.3389/fendo.2022.829658
- Trętowicz MM, Scantlebery AML, Schomakers BV, et al. Human whole-blood NAD+ levels do not vary with age or lifestyle interventions. Nat Metab. 2026;8(6):1282-1290. PubMed 42135539 · doi:10.1038/s42255-026-01537-5
- Seyedsadjadi N, Berg J, Bilgin AA, et al. High protein intake is associated with low plasma NAD+ levels in a healthy human cohort. PLoS One. 2018;13(8):e0201968. PubMed 30114226 · PMC6095538 · doi:10.1371/journal.pone.0201968